Leerink Partners now expects Eli Lilly's (LLY) Foundayo in diabetes to be approved in 2H26
Tweet Send to a Friend
(Updated - April 16, 2026 11:07 AM EDT)
Leerink Partners analyst David Risinger reiterated an Outperform rating and $1,296.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst David Risinger reiterated an Outperform rating and $1,296.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
